{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:01:44Z","timestamp":1789549304513,"version":"build-2803163510"},"reference-count":97,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Mesenchymal stem\/stromal cells (MSCs) exhibit broad differentiation capability and strong immunoregulatory potential mediated through intercellular communication and the release of diverse paracrine mediators. They represent a promising but still investigational therapeutic approach for managing complications associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). This review provides an updated synthesis of MSC biology, their bidirectional interaction with immune cells, and their functional contribution to the hematopoietic niche. It also evaluates current clinical evidence regarding the therapeutic roles of MSCs and MSC-derived extracellular vesicles (EVs) in acute and chronic graft-versus-host disease (aGVHD\/cGVHD), as well as in poor graft function. Mechanistic insights encompass macrophage polarization toward an anti-inflammatory phenotype, inhibition of dendritic cell maturation, enhancement of regulatory T-cell expansion, and modulation of cytokine signaling pathways. Within the bone marrow milieu, MSCs contribute to stromal restoration and angiogenic repair. Recent phase II\/III trials in steroid-refractory (SR)-aGVHD have demonstrated overall response rates ranging from 48 to 71%. Efficacy appears particularly enhanced in pediatric patients and with early MSC administration. Across studies, MSC therapy shows a favorable safety profile; however, heterogeneity in response and inconsistent survival outcomes remain notable limitations. For poor graft function, limited prospective studies indicate hematopoietic recovery following third-party MSC infusions, and combination approaches such as co-administration with thrombopoietin receptor agonists are under investigation. MSC-derived EVs emulate many immunomodulatory effects of their parental cells with a potentially safer profile, though clinical validation remains in its infancy. MSC-oriented interventions hold substantial biological and therapeutic promise, offering a favorable safety margin; however, clinical translation is hindered by product variability, suboptimal engraftment and persistence, and inconsistent efficacy across studies. Future directions should emphasize standardized manufacturing and potency assays, biomarker-driven patient and timing selection, optimized conditioning and dosing strategies, and the systematic appraisal of EV-based or genetically modified MSC products through controlled trials.<\/jats:p>","DOI":"10.3390\/biom16010147","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:01:14Z","timestamp":1768388474000},"page":"147","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mesenchymal Stem\/Stromal Cells: A Review for Its Use After Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2854-0146","authenticated-orcid":false,"given":"Ali","family":"Durdu","sequence":"first","affiliation":[{"name":"Department of Hematology & Apheresis Unit, Ankara Oncology Training and Research Hospital, University of Health Sciences, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Hatipoglu","sequence":"additional","affiliation":[{"name":"Department of Hematology & Apheresis Unit, Ankara Oncology Training and Research Hospital, University of Health Sciences, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Eminoglu","sequence":"additional","affiliation":[{"name":"Department of Hematology & Apheresis Unit, Ankara Oncology Training and Research Hospital, University of Health Sciences, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-663X","authenticated-orcid":false,"given":"Turgay","family":"Ulas","sequence":"additional","affiliation":[{"name":"Department of Hematology & Apheresis Unit, Ankara Oncology Training and Research Hospital, University of Health Sciences, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[{"name":"Department of Hematology & Apheresis Unit, Ankara Oncology Training and Research Hospital, University of Health Sciences, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fevzi","family":"Altuntas","sequence":"additional","affiliation":[{"name":"Department of Hematology & Apheresis Unit, Ankara Oncology Training and Research Hospital, University of Health Sciences, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/stem.269","article-title":"Mesenchymal stromal cells: Current understanding and clinical status","volume":"28","author":"Salem","year":"2010","journal-title":"Stem Cells"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1073\/pnas.0437997100","article-title":"Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma","volume":"100","author":"Spees","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/1381612053507495","article-title":"Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system","volume":"11","author":"Phinney","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1096\/fj.09-148775","article-title":"Keratinocyte proximity and contact can play a significant role in determining mesenchymal stem cell fate in human tissue","volume":"25","author":"Sivamani","year":"2011","journal-title":"FASEB J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2217\/rme-2019-0119","article-title":"Umbilical cord-derived mesenchymal stem cells in neurodegenerative disorders: From literature to clinical practice","volume":"15","author":"Reyhani","year":"2020","journal-title":"Regen. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yang, G., Fan, X., Mazhar, M., Yang, S., Xu, H., Dechsupa, N., and Wang, L. (2022). Mesenchymal stem cell application and its therapeutic mechanisms in intracerebral hemorrhage. Front. Cell. Neurosci., 16.","DOI":"10.3389\/fncel.2022.898497"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7716","DOI":"10.1038\/s41598-018-25700-5","article-title":"The cytokine secretion profile of mesenchymal stromal cells is determined by surface structure of the microenvironment","volume":"8","author":"Leuning","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","article-title":"Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT\u00ae) Mesenchymal Stromal Cell Committee position statement on nomenclature","volume":"21","author":"Viswanathan","year":"2019","journal-title":"Cytotherapy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00018-017-2473-5","article-title":"Interactions between mesenchymal stem cells and the immune system","volume":"74","author":"Li","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","article-title":"Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells","volume":"363","author":"Rasmusson","year":"2004","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3727\/096368912X661319","article-title":"Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: A pilot prospective study","volume":"23","author":"Liu","year":"2014","journal-title":"Cell Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Huang, Y., Wu, Q., and Tam, P.K.H. (2022). Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231710023"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/stem.2509","article-title":"Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression","volume":"35","author":"Davies","year":"2017","journal-title":"Stem Cells"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13287-021-02138-7","article-title":"Advances in mesenchymal stem cell exosomes: A review","volume":"12","author":"Tang","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-025-02313-9","article-title":"Mesenchymal stem cells in treating human diseases: Molecular mechanisms and clinical studies","volume":"10","author":"Han","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jor.1100090504","article-title":"Mesenchymal stem cells","volume":"9","author":"Caplan","year":"1991","journal-title":"J. Orthop. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6940283","DOI":"10.1155\/2016\/6940283","article-title":"Stem cells applications in regenerative medicine and disease therapeutics","volume":"2016","author":"Mahla","year":"2016","journal-title":"Int. J. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: Clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sobacchi, C., Palagano, E., Villa, A., and Menale, C. (2017). Soluble factors on stage to direct mesenchymal stem cells fate. Front. Bioeng. Biotechnol., 5.","DOI":"10.3389\/fbioe.2017.00032"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"31183","DOI":"10.1038\/s41598-025-03806-x","article-title":"Hypoxia Boosts Pluripotent-Like Muse Cell Ratio in Mesenchymal Stromal Cells and Upregulates Pluripotency Gene Expression","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13287-023-03587-y","article-title":"The Heterogeneity of Mesenchymal Stem Cells: An Important Issue to Be Addressed in Cell Therapy","volume":"14","author":"Li","year":"2023","journal-title":"Stem Cell Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Yamamoto, Y., Xiao, Z., and Ochiya, T. (2019). The immunomodulatory functions of mesenchymal stromal\/stem cells mediated via paracrine activity. J. Clin. Med., 8.","DOI":"10.3390\/jcm8071025"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/stem.3357","article-title":"Mesenchymal stromal cell-mediated immune regulation: A promising remedy in the therapy of type 2 diabetes mellitus","volume":"39","author":"Chen","year":"2021","journal-title":"Stem Cells"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Reis, M., Mavin, E., Nicholson, L., Green, K., Dickinson, A.M., and Wang, X.N. (2018). Mesenchymal stromal cell-derived extracellular vesicles attenuate dendritic cell maturation and function. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02538"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lu, D., Xu, Y., Liu, Q., and Zhang, Q. (2021). Mesenchymal stem cell-macrophage crosstalk and maintenance of inflammatory microenvironment homeostasis. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.681171"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"38308","DOI":"10.1038\/srep38308","article-title":"Human mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE2-dependent mechanism","volume":"6","author":"Vasandan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.imbio.2018.08.002","article-title":"Immunomodulatory effects of mesenchymal stem cells on leukocytes with emphasis on neutrophils","volume":"223","author":"Salami","year":"2018","journal-title":"Immunobiology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Guo, R., Liang, Q., He, Y., Wang, C., Jiang, J., Chen, T., Zhang, D., and Hu, K. (2023). Mesenchymal stromal cells-derived extracellular vesicles regulate dendritic cell functions in dry eye disease. Cells, 12.","DOI":"10.2139\/ssrn.4197800"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","article-title":"Mesenchymal stem cells and immunomodulation: Current status and future prospects","volume":"7","author":"Gao","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e12712","DOI":"10.1111\/cpr.12712","article-title":"Immune modulation by mesenchymal stem cells","volume":"53","author":"Jiang","year":"2020","journal-title":"Cell Prolif."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.exphem.2007.11.007","article-title":"Mesenchymal cells recruit and regulate T regulatory cells","volume":"36","author":"Moretti","year":"2008","journal-title":"Exp. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/eji.201242643","article-title":"Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction","volume":"43","author":"Sportoletti","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3349\/ymj.2017.58.5.1031","article-title":"Immune tolerance of human dental pulp-derived mesenchymal stem cells mediated by CD4\u207aCD25\u207aFoxP3\u207a regulatory T-cells and induced by TGF-\u03b21 and IL-10","volume":"58","author":"Hong","year":"2017","journal-title":"Yonsei Med. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-023-01022-z","article-title":"Current perspectives on mesenchymal stromal cell therapy for graft versus host disease","volume":"20","author":"Kadri","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1182\/blood-2010-02-270777","article-title":"Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells","volume":"116","author":"Gieseke","year":"2010","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/scrt537","article-title":"Effect of human bone marrow mesenchymal stromal cells on cytokine production by peripheral blood naive, memory, and effector T cells","volume":"6","author":"Laranjeira","year":"2015","journal-title":"Stem Cell Res. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Draguet, F., Bouland, C., Dubois, N., Bron, D., Meuleman, N., Stamatopoulos, B., and Lagneaux, L. (2023). Potential of mesenchymal stromal cell-derived extracellular vesicles as natural nanocarriers: Concise review. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020558"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1634\/stemcells.2007-0454","article-title":"Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling","volume":"26","author":"Liotta","year":"2008","journal-title":"Stem Cells"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13287-016-0363-7","article-title":"Mechanisms of mesenchymal stem\/stromal cell function","volume":"7","author":"Spees","year":"2016","journal-title":"Stem Cell Res. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1634\/stemcells.2007-0226","article-title":"Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis","volume":"25","author":"Wu","year":"2007","journal-title":"Stem Cells"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.scr.2009.12.003","article-title":"Exosome secreted by MSC reduces myocardial ischemia\/reperfusion injury","volume":"4","author":"Lai","year":"2010","journal-title":"Stem Cell Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mt.2015.44","article-title":"Mesenchymal stem cell-derived extracellular vesicles: Toward cell-free therapeutic applications","volume":"23","author":"Rani","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.201211138","article-title":"Extracellular vesicles: Exosomes, microvesicles, and friends","volume":"200","author":"Raposo","year":"2013","journal-title":"J. Cell Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1084\/jem.183.3.1161","article-title":"B lymphocytes secrete antigen-presenting vesicles","volume":"183","author":"Raposo","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ncb1800","article-title":"Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers","volume":"10","author":"Skog","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1096\/fba.2020-00127","article-title":"The ins and outs of microvesicles","volume":"3","author":"Clancy","year":"2021","journal-title":"FASEB Bioadv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bbmt.2013.11.033","article-title":"Treatment of graft versus host disease with mesenchymal stromal cells: A phase I study on 40 adult and pediatric patients","volume":"20","author":"Introna","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/2040620713489842","article-title":"Treatment and management of graft-versus-host disease: Improving response and survival","volume":"4","author":"Garnett","year":"2013","journal-title":"Ther. Adv. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2014-01-514752","article-title":"Current issues in chronic graft-versus-host disease","volume":"124","author":"Ritz","year":"2014","journal-title":"Blood"},{"key":"ref_52","unstructured":"Phelan, R., Arora, M., and Chen, M. (2021, September 29). Current Use and Outcome of Hematopoietic Stem Cell Transplantation: CIBMTR US Summary Slides. Available online: https:\/\/www.cibmtr.org\/ReferenceCenter\/SlidesReports\/SummarySlides\/Pages\/index.aspx."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41409-018-0092-x","article-title":"Biomarkers in chronic graft-versus-host disease: Quo vadis?","volume":"53","author":"Wolff","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ajh.25717","article-title":"Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis","volume":"95","author":"Goklemez","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood.2021013244","article-title":"Metabolomic identification of \u03b1-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease","volume":"139","author":"Subburaj","year":"2022","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1182\/bloodadvances.2022007715","article-title":"A diagnostic classifier for pediatric chronic graft-versus-host disease: Results of the ABLE\/PBMTC 1202 study","volume":"7","author":"Cuvelier","year":"2023","journal-title":"Blood Adv."},{"key":"ref_57","unstructured":"Food and Drug Administration (2025, November 10). FDA Approves Ruxolitinib for Acute Graft Versus-Host Disease, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ruxolitinib-acute-graft-versus-host-disease."},{"key":"ref_58","unstructured":"Food and Drug Administration (2025, November 10). FDA Approves Ruxolitinib for Chronic Graft-Versus-Host Disease, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ruxolitinib-chronic-graft-versus-host-disease."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study","volume":"371","author":"Frassoni","year":"2008","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41409-018-0102-z","article-title":"Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)","volume":"53","author":"Bader","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Lalu, M.M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B.W., Marshall, J.C., Granton, J., Stewart, D.J., and Canadian Critical Care Trials Group (2012). Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047559"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bcmd.2007.06.021","article-title":"Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation","volume":"40","author":"Kordowich","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/stem.1118","article-title":"Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation","volume":"30","author":"Batsis","year":"2012","journal-title":"Stem Cells"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00277-018-3250-8","article-title":"Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: Characteristics and risk factors for infectious complications","volume":"97","author":"Stoma","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.bbmt.2019.08.029","article-title":"A phase 3 randomized study of Remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease","volume":"26","author":"Kebriaei","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/01.tp.0000214462.63943.14","article-title":"Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease","volume":"81","author":"Uzunel","year":"2006","journal-title":"Transplantation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/bmt.2017.177","article-title":"Mesenchymal stromal cells for steroid-refractory acute GvHD","volume":"52","author":"Regidor","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12185-015-1915-9","article-title":"Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: A phase II\/III study","volume":"103","author":"Muroi","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bbmt.2014.09.030","article-title":"Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation","volume":"21","author":"Zhao","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/bmt.2016.317","article-title":"Good responses but high TRM in adult patients after MSC therapy for GvHD","volume":"52","author":"Salmenniemi","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.15749","article-title":"Mesenchymal stromal cells for acute graft-versus-host disease: Response at 1 week predicts probability of survival","volume":"185","author":"Galleu","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.bbmt.2014.06.015","article-title":"Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease","volume":"20","author":"Redondo","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41409-021-01304-y","article-title":"Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: Real-world evidence","volume":"56","author":"Murata","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Servais, S., Baron, F., Lechanteur, C., Seidel, L., Baudoux, E., Briquet, A., Selleslag, D., Maertens, J., Poire, X., and Schroyens, W. (2023). Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1106464"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease\u2014Biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41409-021-01389-5","article-title":"Steroid-refractory chronic graft-versus-host disease: Treatment options and patient management","volume":"56","author":"Wolff","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12879","article-title":"Immunosenescence: The importance of considering age in health and disease","volume":"187","author":"Weinberger","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bbmt.2013.11.001","article-title":"Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients","volume":"20","author":"Kurtzberg","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/stem.2224","article-title":"Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: Clinical responses and long-term outcome","volume":"34","author":"Kramer","year":"2016","journal-title":"Stem Cells"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"20590","DOI":"10.18632\/oncotarget.25020","article-title":"Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: A multicenter prospective study","volume":"9","author":"Servais","year":"2018","journal-title":"Oncotarget"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-022-01240-4","article-title":"Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: A multicenter, randomized, phase 3, open-label trial","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"104051","DOI":"10.1016\/j.transci.2024.104051","article-title":"Are mesenchymal stem cells still effective in acute GvHD management?","volume":"64","author":"Ulu","year":"2025","journal-title":"Transfus. Apher. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1200\/JCO.2015.65.3642","article-title":"Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation","volume":"34","author":"Gao","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"0300060520920438","DOI":"10.1177\/0300060520920438","article-title":"Pre-infusion single-dose mesenchymal stem cells promote platelet engraftment and decrease severe acute graft versus host disease without relapse in haploidentical peripheral blood stem cell transplantation","volume":"48","author":"Wang","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/s13287-024-04064-w","article-title":"Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: A double-blind randomized study and literature review","volume":"15","author":"Lombardo","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jamaoncol.2023.5757","article-title":"Mesenchymal stem cells for prophylaxis of chronic graft-vs-host disease after haploidentical hematopoietic stem cell transplant: An open-label randomized clinical trial","volume":"10","author":"Huang","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO-24-02119","article-title":"Sequential infusion of mesenchymal stem cell for graft-versus-host disease prevention in haploidentical hematopoietic stem cell transplantation: An open-label, multicenter, randomized controlled clinical trial","volume":"43","author":"Yao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/bloodadvances.2021004537","article-title":"Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation","volume":"6","author":"Prabahran","year":"2022","journal-title":"Blood Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1080\/10428194.2021.1872072","article-title":"Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation","volume":"62","author":"Prabahran","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.bbmt.2019.12.003","article-title":"Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation","volume":"26","author":"Mahat","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"877.e1","DOI":"10.1016\/j.jtct.2021.07.012","article-title":"Outcomes with CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis","volume":"27","author":"Shahzad","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Man, Y., Lu, Z., Yao, X., Gong, Y., Yang, T., and Wang, Y. (2022). Recent advancements in poor graft function following hematopoietic stem cell transplantation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.911174"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s13287-021-02304-x","article-title":"Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis","volume":"12","author":"Li","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.bbmt.2018.06.021","article-title":"Dysfunctional bone marrow mesenchymal stem cells in patients with poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Song","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.bbmt.2019.05.036","article-title":"Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Zhao","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Zhu, L., Liu, J., Kong, P., Gao, S., Wang, L., Liu, H., Zhang, C., Gao, L., Feng, Y., and Chen, T. (2022). Analysis of the efficacy and safety of avatrombopag combined with MSCs for the treatment of thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.910893"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/1\/147\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:28:31Z","timestamp":1768390111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/1\/147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["biom16010147"],"URL":"https:\/\/doi.org\/10.3390\/biom16010147","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]}}}